SSRIs and tinnitus: paradoxical link, mixed evidence

Selective serotonin reuptake inhibitors occupy an unusual position in the tinnitus literature. They appear on lists of medications that can cause tinnitus. They also appear in clinical discussions of medications that help patients cope with tinnitus. The apparent contradiction is not quite the paradox it seems, but it does require understanding what kind of evidence supports each claim.

The short version is this: SSRIs are not classified as ototoxic drugs in the way that aminoglycoside antibiotics or cisplatin are. They do not damage cochlear hair cells. But pharmacovigilance databases contain many tinnitus reports associated with SSRI use, and the mechanism linking serotonin to central auditory processing is real enough that neither causation nor therapeutic benefit can be dismissed without engaging with the evidence.

Serotonin in the auditory system

Serotonin is not primarily an auditory neurotransmitter, but serotonergic projections from the raphe nuclei reach the auditory cortex, inferior colliculus, and cochlear nucleus. At these synapses, serotonin modulates neural excitability, influencing how auditory signals are processed rather than generated at the cochlear level.

This central modulatory role is why SSRIs are plausibly connected to tinnitus on both sides of the equation. Increasing serotonin availability in auditory circuits could in theory either reduce tinnitus-related neural hyperactivity (a therapeutic mechanism) or, under different circumstances, alter baseline firing rates in ways that generate or worsen phantom auditory percepts.

The NIH/NIDCD notes that tinnitus is not exclusively a cochlear phenomenon. Central auditory changes are understood to play a major role in chronic tinnitus. This is the context in which SSRIs interact with tinnitus.

SSRI-induced tinnitus: what the pharmacovigilance data show

Spontaneous reporting databases (FDA Adverse Event Reporting System, WHO VigiBase) contain tinnitus as an adverse event associated with all major SSRIs. A PubMed Central review of drug-induced tinnitus notes that SSRIs are among the psychotropic medication classes appearing in these databases, alongside tricyclic antidepressants and some anxiolytics.

Case reports describing new-onset tinnitus after starting an SSRI, with resolution after stopping, meet a basic standard for suspected drug causation. These reports exist across multiple SSRIs: fluoxetine, paroxetine, sertraline, citalopram, and escitalopram all have associated case reports.

The limitations of pharmacovigilance data are well established. Reporting is voluntary, clinical context is often incomplete, and base rates for tinnitus in the population being treated (often patients with anxiety and depression, who are independently at higher risk of tinnitus) make it difficult to separate drug effect from underlying condition. Pharmacovigilance data can generate a signal worth investigating but cannot confirm causation on their own.

The severity and reversibility question

Most reported cases of SSRI-associated tinnitus describe a relatively mild symptom that resolves when the medication is changed or discontinued. This is different from the pattern of ototoxic medications like aminoglycosides, where cochlear damage can be permanent and progressive.

There is no established mechanism by which SSRIs cause structural cochlear damage. The tinnitus, when it occurs, appears to arise from functional changes in central auditory processing rather than from hair cell destruction. This makes reversibility on drug cessation plausible, and most case reports describe resolution within weeks.

Tinnitus emerging during SSRI dose increases is another reported pattern, suggesting a dose-response relationship in susceptible individuals rather than a binary all-or-nothing effect.

Discontinuation syndrome and tinnitus

A distinct category is SSRI discontinuation syndrome. Patients who stop SSRIs abruptly, particularly those with longer half-lives like paroxetine, can experience a cluster of symptoms including dizziness, flu-like feelings, sensory disturbances described as “brain zaps,” and tinnitus. These are generally short-lived and resolve as serotonergic tone restores to baseline.

This discontinuation-related tinnitus should not be interpreted as evidence that the SSRI was beneficial for tinnitus. It reflects the nervous system adjusting to a rapid change in serotonergic signaling. Slow tapering, as opposed to abrupt discontinuation, substantially reduces discontinuation syndrome symptoms.

SSRIs as tinnitus treatment: the clinical trial evidence

Separately from the question of SSRIs causing tinnitus is the question of whether they can treat it. This line of research was motivated partly by the well-documented comorbidity between tinnitus and depression and anxiety: patients with chronic tinnitus have substantially elevated rates of both conditions, and there is biological overlap between the neural circuits involved in tinnitus distress and those regulated by serotonin.

Several randomized controlled trials have studied SSRIs for tinnitus. Paroxetine has been the most studied in this indication. Results have been mixed: some trials found improvement in tinnitus-related distress (anxiety, quality of life, sleep) without meaningful reduction in tinnitus loudness or pitch match. Other trials found no significant advantage over placebo.

The AAO-HNS tinnitus guideline addresses the role of treating comorbid depression and anxiety in tinnitus management. The guideline acknowledges the importance of mental health treatment for patients with tinnitus but does not specifically recommend SSRIs as a tinnitus-specific therapy in the way it does for cognitive behavioral therapy or sound-based interventions.

The distinction matters clinically. Using an SSRI to treat a patient’s depression or anxiety, which are legitimate, evidence-based indications, may secondarily improve their tinnitus experience by improving mood, sleep, and cognitive reactivity. That is a different claim from saying SSRIs reduce tinnitus directly, and the evidence for the latter is weak.

Practical considerations for patients on SSRIs

For patients currently taking SSRIs who develop tinnitus:

• Report the timing of onset relative to starting or dose-changing the medication
• Do not stop the medication abruptly
• Allow the prescribing clinician to assess whether the benefit-risk balance favors a switch or adjustment
• Get audiometric evaluation if the tinnitus is new, unilateral, or accompanied by hearing change

For patients with tinnitus who are considering SSRIs for depression or anxiety:

• The evidence does not support avoiding SSRIs specifically because of tinnitus risk, particularly when there are clear psychiatric indications
• If tinnitus is a concern, the prescribing clinician can note it as a symptom to monitor

The NHS UK notes that any tinnitus that is new, worsening, or accompanied by hearing change warrants evaluation regardless of medication status.

If symptoms persist or change, see an audiologist or physician.